AtriCure Inc. (NASDAQ:ATRC) SVP Justin J. Noznesky sold 4,000 shares of the stock in a transaction on Thursday, February 15th. The shares were sold at an average price of $17.03, for a total transaction of $68,120.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.
AtriCure Inc. (NASDAQ:ATRC) traded down $0.26 during mid-day trading on Friday, reaching $16.96. 165,261 shares of the company traded hands, compared to its average volume of 195,925. The stock has a market cap of $575.85, a P/E ratio of -16.63 and a beta of 0.39. AtriCure Inc. has a 52 week low of $14.88 and a 52 week high of $25.18. The company has a quick ratio of 1.65, a current ratio of 2.28 and a debt-to-equity ratio of 0.20.
Several brokerages have recently weighed in on ATRC. Piper Jaffray Companies reissued a “buy” rating and issued a $24.00 target price on shares of AtriCure in a research note on Sunday, December 10th. BidaskClub raised shares of AtriCure from a “strong sell” rating to a “sell” rating in a research note on Thursday. Needham & Company LLC reduced their target price on shares of AtriCure from $26.00 to $25.00 and set a “buy” rating on the stock in a research note on Thursday, November 2nd. ValuEngine downgraded shares of AtriCure from a “hold” rating to a “sell” rating in a research note on Wednesday, November 15th. Finally, TheStreet downgraded shares of AtriCure from a “c-” rating to a “d+” rating in a research note on Wednesday, November 29th. Two equities research analysts have rated the stock with a sell rating, two have given a hold rating and six have issued a buy rating to the stock. The company currently has an average rating of “Hold” and an average target price of $24.33.
ILLEGAL ACTIVITY WARNING: “AtriCure Inc. (ATRC) SVP Justin J. Noznesky Sells 4,000 Shares” was first published by BBNS and is the sole property of of BBNS. If you are viewing this report on another site, it was stolen and reposted in violation of United States and international trademark and copyright law. The legal version of this report can be viewed at https://baseballnewssource.com/markets/atricure-inc-atrc-svp-justin-j-noznesky-sells-4000-shares/1888669.html.
AtriCure Company Profile
AtriCure, Inc is an atrial fibrillation (Afib) solutions company. The Company develops, manufactures, and sells devices designed primarily for the surgical ablation of cardiac tissue and systems designed for the exclusion of the left atrial appendage. It has various product lines for the ablation of cardiac tissue, including its Isolator Synergy Ablation System, for the treatment of persistent and longstanding persistent forms of Afib in patients undergoing certain open concomitant procedures.
Receive News & Ratings for AtriCure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AtriCure and related companies with MarketBeat.com's FREE daily email newsletter.